Menu
EyePoint Pharmaceuticals to Participate in Fireside Chat at the Jefferies Virtual Healthcare Conference
Published on 2021-26-05
EyePoint Pharmaceuticals Announces Completion of Enrollment of Phase 1 DAVIO Clinical Trial of EYP-1901 for the Potential Treatment of Wet AMD
Published on 2021-25-05
EyePoint Pharmaceuticals Reports First Quarter 2021 Financial Results and Highlights Recent Corporate Developments
Published on 2021-05-05
EyePoint Pharmaceuticals to Report First Quarter 2021 Financial Results and Discuss Recent Corporate Developments on May 5, 2021
Published on 2021-04-28
EyePoint Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Highlights Recent Corporate Developments
Published on 2021-03-04
EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences
Published on 2021-02-25
EyePoint Pharmaceuticals to Report Fourth Quarter and Full Year 2020 Financial Results on March 4, 2021
Published on 2021-02-25
EyePoint Pharmaceuticals Announces Closing of $115 Million Public Offering of Common Stock
Published on 2021-02-04
EyePoint Pharmaceuticals Announces Pricing of Public Offering of Common Stock
Published on 2021-02-01
EyePoint Pharmaceuticals Announces Proposed Public Offering of Common Stock
Published on 2021-02-01
EyePoint and the EyePoint logo are registered trademarks of EyePoint Pharmaceuticals, Inc.
©2021 EyePoint Pharmaceuticals, Inc. All rights reserved.
EyePoint and the EyePoint logo are registered trademarks of EyePoint Pharmaceuticals, Inc. With an Eye on Patients is a trademark of EyePoint Pharmaceuticals, Inc.
©2021 EyePoint Pharmaceuticals, Inc. All rights reserved.
EyePoint, the EyePoint logo, and Delivering Innovation to the Eye are registered trademarks of EyePoint Pharmaceuticals, Inc.
©2021 EyePoint Pharmaceuticals, Inc. All rights reserved.
EyePoint, the EyePoint logo, YUTIQ, Durasert, and DEXYCU are registered trademarks of EyePoint Pharmaceuticals, Inc. Verisome is a registered trademark of Ramscor, Inc. All other trademarks are the property of their respective owners.
©2021 EyePoint Pharmaceuticals, Inc. All rights reserved.
EyePoint, the EyePoint logo, YUTIQ, and Durasert are registered trademarks of EyePoint Pharmaceuticals, Inc.
©2021 EyePoint Pharmaceuticals, Inc. All rights reserved.
EyePoint, the EyePoint logo, the YUTIQ logo, and the DEXYCU logo are registered trademarks of EyePoint Pharmaceuticals, Inc.
©2021 EyePoint Pharmaceuticals, Inc. All rights reserved.
EyePoint, the EyePoint logo, YUTIQ, the YUTIQ logo, and Durasert are registered trademarks of EyePoint Pharmaceuticals, Inc.
©2021 EyePoint Pharmaceuticals, Inc. All rights reserved.
EyePoint, the EyePoint logo, DEXYCU, and the DEXYCU logo are registered trademarks of EyePoint Pharmaceuticals, Inc.
©2021 EyePoint Pharmaceuticals, Inc. All rights reserved.
EyePoint, the EyePoint logo, Durasert, YUTIQ, and DEXYCU are registered trademarks of EyePoint Pharmaceuticals, Inc.
©2021 EyePoint Pharmaceuticals, Inc. All rights reserved.
EyePoint, the EyePoint logo, YUTIQ, and DEXYCU are registered trademarks of EyePoint Pharmaceuticals, Inc.
©2021 EyePoint Pharmaceuticals, Inc. All rights reserved.